Francois Xavier Caroli-Bosc

Francois Xavier Caroli-Bosc

Auto-generated profile, based on publicly available information

Francois Xavier Caroli-Bosc

Department of Gastroenterology, University Hospital Centre, Angers, France

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
CCCaroline Charlier
Caroline Charlier
ÉPÉlodie Perrodeau
Élodie Perrodeau
Alexandre LeclercqAlexandre Leclercq
Alexandre Leclercq
BCBenoît Cazenave
Benoît Cazenave
BPBenoît Pilmis
Benoît Pilmis
CZChristian Zumbo
Christian Zumbo
Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its clinical features and prognostic factors. MONALISA was a national prospective observational cohort study. We enrolled eligible cases declared to the National Reference Center for Listeria (all microbiologically proven) between Nov 3, 2009, and July 31, 2013, in the context of mandatory reporting. The outcomes were analysis of clinical features, characterisation of Listeria isolates, and determination of predictors of 3-month mortality or persisting impairment using logistic regression. A hierarchical clustering on principal components was also done for neurological and bacteraemic cases. The study is registered at ClinicalTrials.gov, number NCT01520597. We enrolled 818 cases from 372 centres, including 107 maternal-neonatal infections, 427 cases of bacteraemia, and 252 cases of neurolisteriosis. Only five (5%) of 107 pregnant women had an uneventful outcome. 26 (24%) of 107 mothers experienced fetal loss, but never after 29 weeks of gestation or beyond 2 days of admission to hospital. Neurolisteriosis presented as meningoencephalitis in 212 (84%) of 252 patients; brainstem involvement was only reported in 42 (17%) of 252 patients. 3-month mortality was higher for bacteraemia than neurolisteriosis (hazard ratio [HR] 0·54 [95% CI 0·41-0·69], p<0·0001). For both bacteraemia and neurolisteriosis, the strongest mortality predictors were ongoing cancer (odds ratio [OR] 5·19 [95% CI 3·01-8·95], p<0·0001), multi-organ failure (OR 7·98 [4·32-14·72], p<0·0001), aggravation of any pre-existing organ dysfunction (OR 4·35 [2·79-6·81], p<0·0001), and monocytopenia (OR 3·70 [1·82-7·49], p=0·0003). Neurolisteriosis mortality was higher in blood-culture positive patients (OR 3·67 [1·60-8·40], p=0·002) or those receiving adjunctive dexamethasone (OR 4·58 [1·50-13·98], p=0·008). The severity of listeriosis is higher than reported elsewhere. We found evidence of a significantly reduced survival in patients with neurolisteriosis treated with adjunctive dexamethasone, and also determined the time window for fetal losses. MONALISA provides important new data to improve management and predict outcome in listeriosis. Programme Hospitalier Recherche Clinique, Institut Pasteur, Inserm, French Public Health Agency.

1 January 1997 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
SBSoumeya Bekri
Soumeya Bekri
JAJ. Adélaïde
J. Adélaïde
SMSandra Merscher
Sandra Merscher
JGJ. Grosgeorge
J. Grosgeorge
FCF. Caroli-Bosc
F. Caroli-Bosc
PGP. Gaudray
P. Gaudray
Amplification of loci present on band q13 of human chromosome 11 is a feature of a subset of estrogen receptor positive breast carcinomas prone to metastasis. As many as five distinct amplification units have been described on 11q13. They include particularly a genomic area encompassing the GARP gene at 11q13.5→q14.1. We have reassessed our current knowledge of this region, located telomeric to CCND1 and EMS1, which is amplified in 7–10% of mammary tumors. The loose definition of the driving forces of these amplification events led us to map accurately the boundaries of the amplifiable region, and thus to contribute a physical and transcriptional map of a 3-Mb region of chromosome 11. Four new genes were placed on the regional map, namely CBP2, CLNSIA, UVRAG, and PAKl. We have narrowed the core of the 11q13→q14 amplicon to a 350-kb area encompassing D11S533, mostly on its telomeric side. The map reported here represents an indispensable step toward sequencing the entire region, and thus toward uncovering gene(s) which play(s) a critical role in breast cancer progression.

1 May 2013 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
VBValérie Bernard
Valérie Bernard
CLCatherine Lombard-Bohas
Catherine Lombard-Bohas
MTMarie-Caroline Taquet
Marie-Caroline Taquet
FCFrançois-Xavier Caroli-Bosc
François-Xavier Caroli-Bosc
PRPhilippe Ruszniewski
Philippe Ruszniewski
EBEric Baudin
Eric Baudin
Background: Refractory hypoglycemia in patients with metastatic insulinoma is an important cause of morbidity and mortality. Everolimus could be a new therapeutic option.Methods: Within the French Group, we conducted a retrospective, multicentric study of endocrine tumors to evaluate the time to the first recurrence of symptomatic hypoglycemia, after everolimus initiation, in patients with metastatic insulinoma and refractory hypoglycemia. Ongoing hyperglycemic medical options, tumor response, and safety information were recorded.Results: Twelve patients with metastatic insulinoma and refractory hypoglycemia who were treated with everolimus between May 2007 and June 2011 were reviewed. Everolimus (starting dose, 10 mg/day, except in one patient, 5 mg/day) was given after a median of four previous therapeutic lines. Medication aimed at normalizing blood glucose levels in 11 patients. After a median duration of 6.5 months (range 1–35+ months), median time to the first recurrence of symptomatic hypoglycemia was 6.5 months (range 0 to 35+ months). Three patients discontinued everolimus because of cardiac and/or pulmonary adverse events at 1, 1.5, and 7 months after initiation, which led to two deaths. Three patients discontinued everolimus because of tumor progression at 2, 3, and 10 months after initiation, without recurrence of hypoglycemia.Conclusion: Everolimus appears to be a new effective treatment for patients with metastatic insulinoma and refractory hypoglycemia. Tolerance should be carefully monitored.

1 March 2000 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
RDRémi Dumas
Rémi Dumas
NDNicolas Demuth
Nicolas Demuth
MBMartin Buckley
Martin Buckley
EPEmmanuel Paul Peten
Emmanuel Paul Peten
TMThierry Manos
Thierry Manos
JDJean-Pierre Delmont
Jean-Pierre Delmont

11 July 2005 in Gut
Verified
Journal Article
Closed access
TPT Piche
T Piche
GVG Vanbiervliet
G Vanbiervliet
FCF Cherikh
F Cherikh
ZAZ Antoun
Z Antoun
PHP M Huet
P M Huet
ATA Tran
A Tran
Background and aims: There are no available effective therapies for fatigue associated with chronic hepatitis C (CHC). The serotonin antagonist ondansetron has been shown to be effective in the chronic fatigue syndrome. In this randomised, placebo controlled, double blind trial, we investigated the effect of orally administered ondansetron on fatigue in CHC. Methods: Thirty six patients with CHC were included if fatigue was their predominant symptom and they scored more than 4 on a visual analogue scale (0–10). During the study, fatigue and depression were measured on days 0, 15, 30, and 60 using a validated self report questionnaire (fatigue impact scale and Beck depression inventory). Patients were randomised to receive ondansetron tablets 4 mg twice daily or placebo for one month followed by an additional four weeks of observation. Results: Fatigue score was 85.4 (28.2) and 98.2 (26.9) in the ondansetron and placebo groups, respectively (NS). Ondansetron significantly reduced the fatigue score with more than 30% improvement on day 15 (57.1 (38.9); p<0.01), day 30 (54.5 (37.6); p<0.01), and day 60 (60.8 (37.3); p<0.01) whereas placebo did not. Overall, the reduction in fatigue was significantly higher with ondansetron compared with placebo (ANOVA for repeated measurements) for the whole follow up period (p = 0.03) or for the treatment period only (p = 0.04). Ondansetron also significantly reduced depression scores. Conclusions: The 5-hydroxytryptamine receptor type 3 antagonist ondansetron had a significant positive effect on fatigue in CHC. These observations support the concept that fatigue involves serotoninergic pathways and may encourage further evaluations of the efficacy of ondansetron on fatigue in chronic liver diseases.

1 March 2008 in European Journal of Cancer
Verified
Journal Article
Closed access
MDM. Doffoël
M. Doffoël
FBF. Bonnetain
F. Bonnetain
OBO. Bouché
O. Bouché
DVD. Vetter
D. Vetter
AAA. Abergel
A. Abergel
LBL. Bedenne
L. Bedenne